Senti Biosciences Inc(原名:Dynamics Special Purpose Corp.)是一家临床前生物技术公司。该公司正在开发利用它的基因电路平台技术设计的细胞和基因疗法,以治愈疾病。该公司的先进的基因电路候选产品针对用于肿瘤学的同种异体CAR-NK细胞。该公司的临床前阶段候选产品包括SENTI-202、SENTI-301和SENTI-401。它正在开发它的SENTI-202候选产品作为逻辑门控(OR+NOT)同种异体CAR-NK细胞疗法,旨在靶向和消除急性髓性白血病(AML)细胞,同时保留健康的骨髓。该公司的SENTI-301候选产品是一种多臂同种异体CAR-NK细胞疗法,正在开发用于治疗肝细胞癌(HCC)。该公司的SENTI-401候选产品是一种逻辑门控同种异体CAR-NK细胞疗法,它正在开发以靶向和消除结肠直肠癌(CRC)细胞。基因电路平台是它的技术平台。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Timothy K. Lu | Co-Founder, CEO & Director | 2018 | 45 |
| James J. Collins | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director | 2022 | 59 |
| Wilson Wong | Scientific Co-Founder & Member of Scientific Advisory Board | - | - |
| Edward T. Mathers | Independent Director | 2016 | 66 |
| Brenda G. Cooperstone | Independent Director | 2019 | 61 |
| Frances D. Schulz | Independent Director | 2024 | 62 |
| Lawrence Fong | Member of Scientific Advisory Board | - | - |
| Martin Fussenegger | Member of Scientific Advisory Board | - | - |
| Ahmad Khalil | Member of Scientific Advisory Board | - | - |
| Michael Andreeff | Member of Scientific Advisory Board | - | - |
| Michael Kalos | Member of Scientific Advisory Board | 2021 | - |
| Michael D. Varney | Member of Scientific Advisory Board | 2021 | 68 |
| Robin G. Taylor | Member of Scientific Advisory Board | 2021 | - |
| Donald F. Tang | Director | 2024 | 43 |
| Feng Hsiung | Independent Director | 2025 | 51 |
| Bryan Daniel Baum | Director | 2025 | - |